Institutional flow

Institutional Flow — Scan of Sep 12, 2026

Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.

Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
4funds adding
5new positions
$4.27Bheld by those funds

AIThis scan

Scan compared the 2026-06-30 13F window (filed Aug 14) to 2026-03-31 across Berkshire, Bridgewater, Renaissance, Citadel and Two Sigma — all five funds returned holdings. Roughly 977 CUSIPs cleared the mechanical accumulation filter (net buyers > net sellers, ≥25% Q/Q aggregate share growth or ≥2 new positions). The top-25 by aggregate dollar delta was culled to five names that also survived the retail-attention screen — Seagate (STX) dominated on delta but was dropped: shares are up 445% year-over-year on HAMR/AI-storage hype, r/wallstreetbets is actively long, and 22 sell-side buy ratings sit against one sell. That's not quiet accumulation anymore. The single most surprising finding: Intercontinental Exchange (ICE) drew brand-new positions from three separate managers — Bridgewater, Renaissance, and Two Sigma — in the same quarter, while Citadel added 73%. That coincidence pattern (one macro shop plus two quants opening simultaneously at $90B market cap) is uncommon and predates the Polymarket close by roughly two months. The other four picks — CME, MPWR, MCK, MDT — sit in structurally low-attention sectors (exchanges, power-management semis, drug distribution, med-devices) where quant plus macro accumulation carries more signal than in AI-adjacent names.

How this scan was run

For each CUSIP in any fund's latest 13F, per-fund shares-now vs shares-prior deltas were computed, aggregated across the five managers, and PUT rows plus sector-ETF, SPAC and bond entries excluded. Mega-cap retail favorites (AAPL/MSFT/NVDA/GOOG/META/AMZN/TSLA) were excluded unless the position was net-new. A candidate qualified when at least two funds accumulated, net buyers exceeded net trimmers, AND either aggregate share count grew ≥25% Q/Q or ≥2 funds opened new positions. Single-fund block buys representing >80% of the aggregate increase were dropped except where the dominant filer was Berkshire (per spec — Buffett block buys are the signal). All five funds returned holdings; none failed. CME and MPWR are heavy on quant accumulation (RenTech/Citadel/Two Sigma), where 13F is partial signal given intra-quarter turnover; both survived because at least one fundamental/macro filer or a genuinely new quant position was present, but thesis weight was reduced accordingly. Retail-attention values are qualitative estimates from Google Trends interest, mainstream news counts, absence from WSB/StockTwits trending lists, and a rough read of options call/put OI. Average entry-price estimates are derived from filing valueUsd ÷ shares at 2026-06-30 quarter-end and are not cost basis. CUSIP-to-ticker resolution was unambiguous for all five names.

#1

ICE

Intercontinental Exchange Inc.
FinancialsMkt cap $89.9BNext earnings Oct 30, 2026
Price
$157.40
Est. fund entry
$123.11+27.9%
Shares held
6.56M
Position value
$807.7M
Funds that added
FundPrior sharesShares nowChange
Bridgewater Associates—38.9KNew position
Renaissance Technologies—1.27MNew position
Citadel Advisors1.86M3.22M+73.3%
Two Sigma Investments—2.03MNew position
Retail attention 3 of 4 signals quiet
Google Trends22/100quiet
News, 30 days18 articlesbusy
Call/put OI1.50quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Three of five funds — Bridgewater, RenTech, Two Sigma — opened brand-new positions in Q2 while Citadel raised its stake 73%; that pattern is unusually broad-based for a $90B name. The likely draw is optionality on Polymarket, where NYSE's parent finalized a $1.6B stake, plus rising insurance-analytics revenue that recasts the mix beyond exchange volume. Bridgewater does not chase — a new position typically reflects a slower macro theme (prediction markets as a legitimate asset class, alternative data). The under-priced catalyst is regulatory clarity for prediction markets: CME is suing the CFTC to block similar approvals, and ICE sits on the winning side of that ruling.

What would prove it wrong

Prediction-market regulation could tighten under new CFTC leadership, and the Polymarket investment is early-stage with an unclear return path. A defensive court ruling in CME's favor would also compress ICE's optionality.

#2

CME

CME Group Inc.
FinancialsMkt cap $99.2BNext earnings Oct 21, 2026
Price
$275.54
Est. fund entry
$220.83+24.8%
Shares held
5.01M
Position value
$1.11B
Funds that added
FundPrior sharesShares nowChange
Renaissance Technologies34.8K680.0K+1854.2%
Citadel Advisors679.4K1.91M+180.9%
Two Sigma Investments1.15M2.42M+110.0%
Retail attention 4 of 4 signals quiet
Google Trends15/100quiet
News, 30 days14 articlesquiet
Call/put OI1.20quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

All three quants piled in during Q2 despite the stock being down 3.8% YTD, with RenTech going from 34,800 to 680,000 shares. The setup is textbook mean-reversion: perpetual-futures competition from Coinbase and Kalshi has compressed CME's multiple even though 85–90% of CME volume is institutional and structurally sticky (per CEO Terry Duffy). Duffy has also sued the CFTC over the perp approvals — a favorable outcome would remove the overhang. Retail is treating the perp-futures narrative as terminal; the buyers here are treating it as noise around a durable rate-and-Treasury-futures franchise, with Q4's Treasury Link launch as the next demonstration of moat.

What would prove it wrong

If Coinbase perpetuals gain institutional traction post-approval, the moat erodes materially. A court loss in CME v. CFTC removes the injunction pathway and cements the competitive threat.

#3

MPWR

Monolithic Power Systems Inc.
Information TechnologyMkt cap $67.9BNext earnings Oct 29, 2026
Price
$1,234.46
Est. fund entry
$1,382.35-10.7%
Shares held
395.0K
Position value
$546.0M
Funds that added
FundPrior sharesShares nowChange
Renaissance Technologies—63.1KNew position
Citadel Advisors63.1K135.7K+115.0%
Two Sigma Investments15.2K193.1K+1168.9%
Retail attention 4 of 4 signals quiet
Google Trends10/100quiet
News, 30 days9 articlesquiet
Call/put OI1.40quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

RenTech opened a fresh 63K-share position; Two Sigma nearly 13x'd its stake to 193K; Citadel added 115%. MPWR supplies power-management ICs into AI accelerator systems (Nvidia HGX, custom silicon) but sits outside the retail AI beta list — a $1,200+ share price and 'boring at first glance' reputation keep it there. Aggregate value/shares at 6/30 implies buying near $1,380; the funds are modestly underwater into Q3, which typically reads as conviction rather than trimming. The catalyst is content share on Blackwell Ultra and Rubin-generation boards, which ramps through late 2026 and doesn't hit consensus estimates until the Q4 print.

What would prove it wrong

Hyperscaler capex normalization or a shift back to internal PMICs at any major AI customer would immediately hit content share. Valuation (~28x forward) leaves no cushion for a miss.

#4

MCK

McKesson Corporation
Health CareMkt cap $106.3BNext earnings Nov 5, 2026
Price
$881.51
Est. fund entry
$755.60+16.7%
Shares held
1.04M
Position value
$787.9M
Funds that added
FundPrior sharesShares nowChange
Bridgewater Associates67.4K70.4K+4.4%
Renaissance Technologies117.2K361.1K+208.0%
Citadel Advisors189.7K601.8K+217.2%
Two Sigma Investments6.20K9.45K+52.4%
Retail attention 4 of 4 signals quiet
Google Trends12/100quiet
News, 30 days15 articlesquiet
Call/put OI1.30quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Four of five funds added, including Bridgewater — the slowest-moving manager on the list, whose portfolio turnover suggests a thesis-driven add rather than a factor tilt. Citadel and RenTech both roughly tripled their share counts. The overhang is the Aug 25 cybersecurity incident, which drove a 5–7% dislocation the funds bought into; distribution networks at this scale have historically resolved these events within a quarter without material earnings impact. The under-priced catalyst is the Precision Medicine Group acquisition ($2.25B) closing into a stronger biopharma commercialization vertical — analyst models still treat MCK as pure drug distribution and haven't repriced the mix.

What would prove it wrong

The cybersecurity incident's ultimate scope is not yet fully disclosed; class-action or federal-contract impact remains a tail risk. Drug-pricing reform legislation is a perpetual headwind for distributors.

#5

MDT

Medtronic plc
Health CareMkt cap $116.4BNext earnings Nov 18, 2026
Price
$90.96
Est. fund entry
$78.23+16.3%
Shares held
13.1M
Position value
$1.02B
Funds that added
FundPrior sharesShares nowChange
Bridgewater Associates255.2K482.5K+89.0%
Renaissance Technologies—3.17MNew position
Citadel Advisors2.45M6.20M+153.1%
Two Sigma Investments626.9K3.24M+417.0%
Retail attention 3 of 4 signals quiet
Google Trends20/100quiet
News, 30 days17 articlesbusy
Call/put OI1.10quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Four funds accumulating, with RenTech opening a 3.2M-share new position and Bridgewater adding 89%. MDT delivered its strongest revenue growth in a decade in fiscal 2026 but shares still trail the S&P; the buyers are exploiting the gap between fundamentals and multiple. Aggregate entry near $78 sits meaningfully below current $91 — the funds are already up, but Citadel's $485M sizing reads as conviction rather than a factor position. The catalyst not yet in consensus is the Hugo robotic-surgery platform reaching commercial inflection in FY27 — Intuitive Surgical currently owns 100% of that market at Intuitive multiples, and MDT trades at roughly half that.

What would prove it wrong

Hugo's commercial ramp has slipped twice; another delay resets the thesis. The Diabetes spinoff has left the growth mix leaner than headline growth suggests, so any med-tech multiple compression hits harder.

All scans

Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones — while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartCreate a free account

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.